Affiliation:
1. Clinical and Health Sciences, University of South Australia, Adelaide, SA 5001, Australia
2. School of Biomedicine, University of Adelaide, Adelaide, SA 5005, Australia
Abstract
Binding of substance P to the tachykinin NK1 receptor is involved in numerous physiological and pathophysiological processes ranging from modulation of sensory and motor function to inflammation, cancer, and brain injury, amongst others. NK1 antagonists therefore have enormous potential as a therapeutic intervention in a wide variety of human disease states, albeit that the clinical potential is yet to be fully realised. In the current review, the role of substance P in the pathophysiology of traumatic brain injury (TBI) will be discussed, summarising both experimental and clinical observations in mild, moderate, and severe TBI. In addition, the potential for NK1 antagonists to be a valuable therapeutic intervention against chronic traumatic encephalopathy (CTE) after repeated concussive brain injury as well as raised intracranial pressure (ICP) following severe TBI will be addressed, highlighting the various pathophysiological processes that are attenuated by the intervention.
Reference72 articles.
1. Centers for Disease Control and Prevention (2023, June 25). Leading Causes of Death and Injury, Available online: https://www.cdc.gov/injury/wisqars/leadingcauses.html.
2. Traumatic brain injury: A silent epidemic;Goldstein;Ann. Neurol.,1990
3. Applying the Bradford Hill criteria for causation to repetitive head impacts and chronic traumatic tncephalopathy;Nowinski;Front. Neurol.,2022
4. Severe traumatic brain injury: Targeted management in the intensive care unit;Stocchetti;Lancet Neurol.,2017
5. Substance P: A pioneer amongst neuropeptides;Hokfelt;J. Intern. Med.,2001